Engineered CD3 Antibodies for Immunosuppression

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2003 Aug 22

PMID 12930354

Citations 3

Authors

L Renders

T Valerius

Affiliations

Soon will be listed here.

Citing Articles

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Yaacov A, Shabat Y J Clin Immunol. 2015; 35(4):399-407.

PMID: 25876706 DOI: 10.1007/s10875-015-0160-6.

Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance.

Yang H, Youm Y, Vandanmagsar B, Ravussin A, Gimble J, Greenway F J Immunol. 2010; 185(3):1836-45.

PMID: 20581149 PMC: 4829921. DOI: 10.4049/jimmunol.1000021.

Muronomab-CD3 for pediatric acute myocarditis.

Perens G, Levi D, Alejos J, Wetzel G Pediatr Cardiol. 2006; 28(1):21-6.

PMID: 17165111 DOI: 10.1007/s00246-006-1322-3.

References

Friend P, Hale G, Chatenoud L, REBELLO P, Bradley J, Thiru S . Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation. 1999; 68(11):1632-7. DOI: 10.1097/00007890-199912150-00005. View

Herold K, Hagopian W, Auger J, Poumian-Ruiz E, Taylor L, Donaldson D . Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002; 346(22):1692-8. DOI: 10.1056/NEJMoa012864. View

Norman D, Vincenti F, de Mattos A, Barry J, Levitt D, Wedel N . Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation. 2001; 70(12):1707-12. DOI: 10.1097/00007890-200012270-00008. View

Shields R, Namenuk A, Hong K, Meng Y, RAE J, Briggs J . High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2000; 276(9):6591-604. DOI: 10.1074/jbc.M009483200. View

Sondermann P, Kaiser J, Jacob U . Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol. 2001; 309(3):737-49. DOI: 10.1006/jmbi.2001.4670. View

Dechant M, Valerius T . IgA antibodies for cancer therapy. Crit Rev Oncol Hematol. 2001; 39(1-2):69-77. DOI: 10.1016/s1040-8428(01)00105-6. View

Waldmann H . Therapeutic approaches for transplantation. Curr Opin Immunol. 2001; 13(5):606-10. DOI: 10.1016/s0952-7915(00)00268-5. View

Utset T, Auger J, Peace D, Zivin R, Xu D, Jolliffe L . Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002; 29(9):1907-13. View

Chatenoud L . CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003; 3(2):123-32. DOI: 10.1038/nri1000. View

10.

Herold K, Burton J, Francois F, Poumian-Ruiz E, Glandt M, Bluestone J . Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003; 111(3):409-18. PMC: 151852. DOI: 10.1172/JCI16090. View

11.

van Sorge N, van der Pol W, van de Winkel J . FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003; 61(3):189-202. DOI: 10.1034/j.1399-0039.2003.00037.x. View

12.

Meijer R, Surachno S, Yong S, Bemelman F, Florquin S, ten Berge I . Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody. Clin Exp Immunol. 2003; 133(3):485-92. PMC: 1808785. DOI: 10.1046/j.1365-2249.2003.02200.x. View

13.

Tax W, Willems H, Reekers P, Capel P, Koene R . Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature. 1983; 304(5925):445-7. DOI: 10.1038/304445a0. View

14.

Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H . Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med. 1989; 320(21):1420-1. DOI: 10.1056/NEJM198905253202117. View

15.

Hirsch R, Bluestone J, DeNenno L, Gress R . Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 1990; 49(6):1117-23. DOI: 10.1097/00007890-199006000-00018. View

16.

Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman S . The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol. 1993; 23(2):403-11. DOI: 10.1002/eji.1830230216. View

17.

Raasveld M, Bemelman F, Schellekens P, van Diepen F, van Dongen A, van Royen E . Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int. 1993; 43(5):1140-9. DOI: 10.1038/ki.1993.160. View

18.

Abbs I, Clark M, Waldmann H, Chatenoud L, Koffman C, Sacks S . Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Ther Immunol. 1994; 1(6):325-31. View

19.

Wilde M, Goa K . Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996; 51(5):865-94. DOI: 10.2165/00003495-199651050-00010. View

20.

Tax W, Tamboer W, Jacobs C, Frenken L, Koene R . Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation. 1997; 63(1):106-12. DOI: 10.1097/00007890-199701150-00020. View